Figure 4

Therapy studies in mice with collagen-induced arthritis. (a) to (d) Mice were immunized according to the full collagen induction protocol, included in the therapy when showing symptoms and injected on days 1, 4 and 7 (arrows). *Fifteen of 50 mice (30%) developed an explosive disease and could not be included in the therapy. Mice received saline subcutaneously (s.c.; squares), 200 μg F8-huIL10 s.c. (circles), 10 μg muTNFR-Fc intravenously (i.v.; triangles) or a combination of F8-huIL10 and muTNFR-Fc (crosses). The clinical score was evaluated daily and expressed as (a) arthritic score or (b) modified arthritic score with mean and standard error of the mean (SEM) of seven mice per group. (c) Paw swelling was measured daily and paw thickness expressed as the mean of all four paws (mean and SEM). (d) Weight was monitored daily and expressed as percent of weight loss (mean and SEM). (e) to (h) Mice were immunized according to the reduced collagen induction protocol. **Six of 60 mice (10%) developed disease too rapidly and could not be included in the therapy. Mice received saline s.c. (squares), 200 μg F8-huIL10 s.c. (circles), 30 μg muTNFR-Fc i.v. (triangles), a combination of F8-huIL10 and muTNFR-Fc (crosses) or 200 μg F8-muIL10 s.c. (open circles). (e) Arthritic score or (f) modified arthritic score with mean and SEM of 10 mice per group. (g) Paw swelling was measured daily and paw thickness expressed as the mean of all four paws (mean and SEM). (h) Weight was monitored daily and expressed as percent of weight loss (mean and SEM). *¹P <0.05, **¹P <0.01 combo versus saline; *²P <0.05, **²P <0.01 muTNFR-Fc versus saline; *³P <0.05 combo versus muTNFR-Fc.